011000.KS
GeneOne Life Science, Inc. [011000.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
011000.KS Stock Summary
Top 10 Correlated Stocks
011000.KS
011000.KS Financial details
Company Rating
Buy
Market Cap
537.63B
Income
-25.84B
Revenue
49.07B
Book val./share
3070.07
Cash/share
-
Dividend
-
Dividend %
-
Employees
61
Optionable
No
Shortable
Yes
Earnings
-
P/E
-18.85
Forward P/E
-
PEG
-4.25
P/S
9.92
P/B
2.26
P/C
-
P/FCF
-5.18
Quick Ratio
-
Current Ratio
2.85
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-368.25
EPS next Y
-
EPS next Q
-
EPS this Y
-14.51%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-20.57%
Revenue last 5Y
7.33%
Revenue Q/Q
-12.79%
EPS Q/Q
-27.97%
-
-
-
-
SMA20
-9.8%
SMA50
-32.76%
SMA100
-32.82%
Inst Own
-
Inst Trans
-
ROA
-10%
ROE
-12%
ROC
-0.15%
Gross Margin
27%
Oper. Margin
-67%
Profit Margin
-53%
Payout
-
Shs Outstand
77.47M
Shs Float
70.54M
-
-
-
-
Target Price
-
52W Range
6480.0-23450.0
52W High
-70.41%
52W Low
+7.1%
RSI
37
Rel Volume
0.41
Avg Volume
766.36K
Volume
310.6K
Perf Week
-5.58%
Perf Month
-26.87%
Perf Quarter
-38.58%
Perf Half Y
-44.48%
-
-
-
-
Beta
-1.83914
-
-
Volatility
239.21%, 754.34%
Prev Close
-1%
Price
6940
Change
-1.84%
011000.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 790.37 | 847.92 | 1.13K | 567.53 | 529.21 | |
| Net income per share | -690.26 | -294.18 | -208.97 | -255.01 | -218.13 | |
| Operating cash flow per share | -117.52 | -179.73 | -34.84 | -217.64 | -66.31 | |
| Free cash flow per share | -129.52 | -269.79 | -117.39 | -441.49 | -1.19K | |
| Cash per share | 658.83 | 561.09 | 479.38 | 1.24K | 1.47K | |
| Book value per share | 1.06K | 727.2 | 659.96 | 1.35K | 2.81K | |
| Tangible book value per share | 946.96 | 714.24 | 644.08 | 1.34K | 2.8K | |
| Share holders equity per share | 1.06K | 727.2 | 659.96 | 1.35K | 2.81K | |
| Interest debt per share | 95.96 | 340.7 | 451.33 | 251.54 | 312.53 | |
| Market cap | 129.06B | 110.88B | 127.36B | 780.24B | 899.48B | |
| Enterprise value | 118.49B | 114.89B | 124.92B | 735.57B | 895.57B | |
| P/E ratio | -5.44 | -9.32 | -16.72 | -41.84 | -56.39 | |
| Price to sales ratio | 4.75 | 3.23 | 3.09 | 18.8 | 23.24 | |
| POCF ratio | -31.95 | -15.25 | -100.28 | -49.02 | -185.49 | |
| PFCF ratio | -28.99 | -10.16 | -29.76 | -24.17 | -10.3 | |
| P/B Ratio | 3.53 | 3.77 | 5.29 | 7.92 | 4.38 | |
| PTB ratio | 3.53 | 3.77 | 5.29 | 7.92 | 4.38 | |
| EV to sales | 4.36 | 3.35 | 3.03 | 17.72 | 23.14 | |
| Enterprise value over EBITDA | -5.83 | -12.69 | -71.1 | -54.18 | -137.14 | |
| EV to operating cash flow | -29.33 | -15.81 | -98.37 | -46.22 | -184.69 | |
| EV to free cash flow | -26.61 | -10.53 | -29.19 | -22.78 | -10.25 | |
| Earnings yield | -0.18 | -0.11 | -0.06 | -0.02 | -0.02 | |
| Free cash flow yield | -0.03 | -0.1 | -0.03 | -0.04 | -0.1 | |
| Debt to equity | 0 | 0 | 0.08 | 0.01 | 0.03 | |
| Debt to assets | 0.2 | 0.4 | 0.53 | 0.28 | 0.18 | |
| Net debt to EBITDA | 0.52 | -0.44 | 1.39 | 3.29 | 0.6 | |
| Current ratio | 4.04 | 2.03 | 1.62 | 2.96 | 3.87 | |
| Interest coverage | -13.49 | -8.09 | -4.17 | -29.37 | -6.17 | |
| Income quality | 0.17 | 0.61 | 0.17 | 0.85 | 0.3 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Research and developement to revenue | 0.31 | 0.17 | 0.14 | 0.2 | 0.3 | |
| Intangibles to total assets | 0.09 | 0.01 | 0.01 | 0.01 | 0 | |
| Capex to operating cash flow | 0.1 | 0.5 | 2.37 | 1.03 | 17.02 | |
| Capex to revenue | -0.02 | -0.11 | -0.07 | -0.39 | -2.13 | |
| Capex to depreciation | -0.37 | -2.82 | -0.88 | -4.07 | -17.82 | |
| Stock based compensation to revenue | 0.31 | 0.06 | 0 | 0 | 0 | |
| Graham number | 4.06K | 2.19K | 1.76K | 2.78K | 3.71K | |
| ROIC | -0.67 | -0.37 | -0.29 | -0.18 | -0.13 | |
| Return on tangible assets | -0.57 | -0.24 | -0.15 | -0.14 | -0.06 | |
| Graham Net | 494.31 | 166.18 | -143.8 | 774.06 | 939.53 | |
| Working capital | 26.08B | 19.37B | 13.94B | 72.06B | 98.71B | |
| Tangible asset value | 32.55B | 28.89B | 23.48B | 97.83B | 204.81B | |
| Net current asset value | 25.56B | 18.3B | 9.5B | 70.7B | 89.12B | |
| Invested capital | 0.04 | 0.42 | 0.6 | 0.18 | 0.09 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 4.59B | 4.21B | 4.59B | 6.88B | 12.21B | |
| Average inventory | 7.59B | 8.06B | 8.52B | 8.3B | 9.49B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 38.86 | 23.81 | 29.54 | 83.47 | 213.69 | |
| Days of inventory on hand | 116.65 | 121.09 | 112.59 | 100.67 | 130.28 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 9.39 | 15.33 | 12.36 | 4.37 | 1.71 | |
| Inventory turnover | 3.13 | 3.01 | 3.24 | 3.63 | 2.8 | |
| ROE | -0.65 | -0.4 | -0.32 | -0.19 | -0.08 | |
| Capex per share | -12 | -90.06 | -82.55 | -223.85 | -1.13K |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 92.86 | 145.4 | 170.13 | 205.1 | 178.85 | |
| Net income per share | -78.41 | -33.3 | -65.88 | -156.41 | -112.66 | |
| Operating cash flow per share | 10.94 | 52.26 | -127.68 | -13.4 | -78.96 | |
| Free cash flow per share | -334.79 | -452.37 | -350.76 | -202.58 | -183.09 | |
| Cash per share | 523.53 | 1.53K | 0 | 0 | 0 | |
| Book value per share | 1.3K | 2.93K | 2.89K | 2.94K | 3.07K | |
| Tangible book value per share | 1.29K | 2.92K | 2.89K | 2.94K | 3.07K | |
| Share holders equity per share | 1.3K | 2.93K | 2.89K | 2.94K | 3.07K | |
| Interest debt per share | 401.93 | 282.56 | -1.98 | 3.11 | -24.42 | |
| Market cap | 1546.68B | 1136.55B | 1048.86B | 722.62B | 667.9B | |
| Enterprise value | 1537.03B | 1132.64B | 1048.86B | 722.62B | 667.9B | |
| P/E ratio | -70.29 | -121.63 | -56.73 | -16.46 | -21.12 | |
| Price to sales ratio | 237.4 | 111.42 | 87.87 | 50.22 | 53.23 | |
| POCF ratio | 2.02K | 310 | -117.09 | -768.82 | -120.56 | |
| PFCF ratio | -65.85 | -35.81 | -42.62 | -50.84 | -52 | |
| P/B Ratio | 16.96 | 5.53 | 5.17 | 3.5 | 3.1 | |
| PTB ratio | 16.96 | 5.53 | 5.17 | 3.5 | 3.1 | |
| EV to sales | 235.92 | 111.03 | 87.87 | 50.22 | 53.23 | |
| Enterprise value over EBITDA | -507.64 | 1.7K | -311.57 | -67.32 | -69.45 | |
| EV to operating cash flow | 2K | 308.93 | -117.09 | -768.82 | -120.56 | |
| EV to free cash flow | -65.44 | -35.69 | -42.62 | -50.84 | -52 | |
| Earnings yield | 0 | 0 | 0 | -0.02 | -0.01 | |
| Free cash flow yield | -0.02 | -0.03 | -0.02 | -0.02 | -0.02 | |
| Debt to equity | 0.09 | 0.03 | 0 | 0 | 0 | |
| Debt to assets | 0.35 | 0.18 | 0.17 | 0.18 | 0.17 | |
| Net debt to EBITDA | 3.19 | -5.88 | 0 | 0 | 0 | |
| Current ratio | 1.48 | 3.87 | 3.48 | 2.98 | 2.85 | |
| Interest coverage | -7.06 | -6.74 | 48.79 | -43 | 4.22 | |
| Income quality | -0.14 | -1.57 | 1.94 | 0.09 | 0.7 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.02 | 0.86 | 1.08 | 0.74 | |
| Research and developement to revenue | 0.4 | 0.38 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -31.61 | -9.66 | 1.75 | 14.12 | 1.32 | |
| Capex to revenue | -3.72 | -3.47 | -1.31 | -0.92 | -0.58 | |
| Capex to depreciation | -18.82 | -28.39 | -11.29 | -9.67 | -5.16 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.51K | 1.48K | 2.07K | 3.22K | 2.79K | |
| ROIC | -0.09 | -0.04 | -0.03 | -0.04 | -0.03 | |
| Return on tangible assets | -0.04 | -0.01 | -0.02 | -0.04 | -0.03 | |
| Graham Net | -89.4 | 979.32 | -603.91 | -655.05 | -634.47 | |
| Working capital | 18.85B | 98.71B | 80.51B | 70.24B | 61.98B | |
| Tangible asset value | 90.53B | 204.81B | 0 | 0 | 0 | |
| Net current asset value | 10.08B | 89.12B | 70.55B | 59.73B | 51B | |
| Invested capital | 0.3 | 0.09 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 190.28 | 176.61 | 0 | 0 | 0 | |
| Days of inventory on hand | 158.2 | 107.67 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.47 | 0.51 | 0 | 0 | 0 | |
| Inventory turnover | 0.57 | 0.84 | 0 | 0 | 0 | |
| ROE | -0.06 | -0.01 | -0.02 | -0.05 | -0.04 | |
| Capex per share | -345.73 | -504.63 | -223.08 | -189.19 | -104.12 |
011000.KS Frequently Asked Questions
What is GeneOne Life Science, Inc. stock symbol ?
GeneOne Life Science, Inc. is a US stock and trading under the symbol 011000.KS
What is GeneOne Life Science, Inc. stock quote today ?
GeneOne Life Science, Inc. stock price is $6940 today.
Is GeneOne Life Science, Inc. stock public?
Yes, GeneOne Life Science, Inc. is a publicly traded company.
Company Profile
- Volume Average 766.36K
- Market Capitalization 537.63B
- Employee 61
- Headquarters Seoul,US
- IPO Date 2000-02-04
-
Website
https://www.genels.com 
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.
